Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Oct;4(8):1298-1305.
doi: 10.4236/jct.2013.48153.

Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma

Ana I Velazquez  1 , David J Inwards  1 , Stephen M Ansell  1 , Ivana N Micallef  1 , Patrick B Johnston  1 , William J Hogan  1 , Svetomir N Markovic  1 , Luis F Porrata  1
Affiliations

Day 100 Absolute Monocyte/Lymphocyte Prognostic Score and Survival Post Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation in Diffuse Large B-Cell Lymphoma

Ana I Velazquez et al. J Cancer Ther. 2013 Oct.

Abstract

Day 100 prognostic factors post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients have not been studied. Thus, we retrospectively examined if day 100 absolute monocyte/lymphocyte prognostic score (AMLPS-100) affects clinical outcomes by landmark analysis from day 100 post-APBHSCT in DLBCL. Only DLBCL patients in complete remission at day 100 post-APBHSCT were evaluated. From 2000 to 2007, 134 consecutive DLBCL patients are qualified for the study. Patients with a day 100 absolute monocyte count (AMC-100) ≥ 630 cells/μL and day 100 absolute lymphocyte count (ALC-100) ≤ 1000 cells/μL experienced inferior overall survival (OS) and progression free survival (PFS). On multivariate analysis, the AMC-100 and ALC-100 remained independent predictors of OS and PFS. Combining both values into the AMLPS-100, the 5-year OS rates for low, intermediate, and high AMLPS-100 risk groups were 94% (95% CI, 83.0% - 98.1%), 70% (95% CI, 58.6% - 80.1%), and 13% (95% CI, 3.4% - 40.5%), respectively; and the 5-year PFS rates were 87% (95% CI, 74.0% - 94.1%), 68% (95% CI, 56.0% - 77.8%), and 13% (95% CI, 3.4% - 40.5%), respectively. The AMLPS-100 is a simple biomarker score that can stratify clinical outcomes from day 100 post-APBHSCT in DLBCL patients.

Keywords: Autologous Peripheral Blood Hematopoietic Stem Cell Transplantation; Diffuse Large B-Cell Lymphoma; Monocyte/Lymphocyte Prognostic Score; Survival.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors declare no conflict of interest.

Figures

Figure 1.
Figure 1.
(a) Kaplan-Meier estimates of overall survival from day 100 post-APBHSCT based on day 100 absolute monocyte count (AMC-100); (b) Kaplan-Meier estimates of progression-free survival from day 100 post-APBHSCT based on day 100 absolute monocyte count (AMC-100); (c) Kaplan-Meier estimates of overall survival from day 100 post-APBHSCT based on day 100 absolute lymphocyte count (ALC-100); and (d) Kaplan-Meier estimates of progression-free survival from day 100 post-APBHSCT based on day 100 absolute lymphocyte count (ALC-100).
Figure 2.
Figure 2.
Kaplan-Meier estimates of overall (a) and progression free (b) survival for the entire cohort of patients stratified by the AMC/ALC prognostic score at day 100 (AMLPS-100, stratifying patients into low risk (ALC-100 > 1000 cells/μL and AMC-100 < 630 cells/μL); intermediate-risk (ALC-100 ≤ 1000 cells/μL or AMC-100 ≥ 630 cells/μL); and high-risk (ALC-100 ≤ 1000 cells/μL and AMC-100 ≥ 630 cells/μL).
See this image and copyright information in PMC

References

    1. DeCook LJ, Thoma M, Huneke T, Johnson ND, R. A., Patnaik MM, et al., “Impact of Lymphocyte and Monocyte Recovery on the Outcomes of Allogeneic Hematopoietic SCT with Fludarabine and Melphalan Conditioning,” Bone Marrow Transplantation, Vol. 48, No. 5, 2013, pp. 708–714. 10.1038/bmt.2012.211 - DOI - PubMed
    1. Bolwell B, Pohlman B, Sobecks R, Andresen S, Brown S, Rybicki L, et al., “ Prognostic Importance of the Platelet Count 100 Days Post Allogeneic Bone Marrow Transplant,” Bone Marrow Transplantation, Vol. 33, No. 4, 2004, pp. 419–423. 10.1038/sj.bmt.1704330 - DOI - PubMed
    1. Kuzmina Z, Eder S, Bohm A, Pernicka E, Vormittag L, Kahs P, et al., “Significant Worse Survival of Patients with NIH-Defined Chronic Graft-versus-Host Disease and Thrombocytopenia or Progressive Onset Type: Results of a Prospective Study,” Leukemia, Vol. 26, No. 4, 2012, pp. 746–756. 10.1038/leu.2011.257 - DOI - PubMed
    1. Holtan SG, Hogan WJ, Elliott MA, Ansell SM, Inwards DJ, Porrata LF, et al., “CD34+ Cell Dose and Establishment of Full Donor Chimerism at Day +100 Are Important Factors for Survival with Reduced-Intensity Conditioning with Fludarabine and Melphalan before Allogeneic Hematopoietic SCT for Hematologic Malignancies,” Bone Marrow Transplantation, Vol. 45, No. 12, 2010, pp. 1699–1703. 10.1038/bmt.2010.49 - DOI - PMC - PubMed
    1. Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef INM, Johnston PB, et al., “The Absolute Monocyte and Lymphocyte Prognostic Score Predicts Survival and Identifies High-Risk Patients in Diffuse Large-B-Cell Lymphoma,” Leukemia, Vol. 25, No. 9, 2011, pp. 1502–1509. 10.1038/leu.2011.112 - DOI - PubMed

LinkOut - more resources